Barrett & Company’s CNS Pharmaceuticals CNSP Stock Holding History

Barrett & Company’s Portfolio CNSP Stock Details CNSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38	Hold	8	–	–	﹤0.01%	704
2026 Q1	$19	Hold	8	–	–	﹤0.01%	651
2025 Q4	$42	Hold	8	–	–	﹤0.01%	659
2025 Q3	$72	Hold	8	–	–	﹤0.01%	632
2025 Q2	$83	Hold	8	–	–	﹤0.01%	633
2025 Q1	$136	Buy	+8	New	+$391	﹤0.01%	613

Barrett & Company's CNSP Position: Q2 2026 in Review

Barrett & Company held its CNS Pharmaceuticals (CNSP) position steady in Q2 2026 at 8 shares worth $38. The position accounts for ﹤0.01% of the portfolio, ranked #704.

Barrett & Company first reported a position in CNSP in Q1 2025 and has held it in 6 quarters since. The position peaked at $136 in Q1 2025. 1 fund tracked by Wall St. Rank holds CNSP as of Q2 2026.

Barrett & Company held 8 shares of CNS Pharmaceuticals worth $38 as of Q2 2026.
Barrett & Company left its CNS Pharmaceuticals share count unchanged in Q2 2026.
CNS Pharmaceuticals made up ﹤0.01% of Barrett & Company's portfolio in Q2 2026, its #704 holding.
Barrett & Company first reported a position in CNS Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Barrett & Company's CNS Pharmaceuticals position peaked at $136 in Q1 2025.
1 fund tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on Barrett & Company's 13F filing for Q2 2026, filed 24 Jul 2026.